These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19899498)

  • 1. Reduced drug costs from switching hemodialysis patients from epoetin alfa in multidose vials to pre-filled syringes.
    Wazny LD; Raymond CB; Do MK; Skwarchuk DE
    CANNT J; 2009; 19(3):39-41. PubMed ID: 19899498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
    Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
    Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Hernán MA
    Am J Kidney Dis; 2007 Oct; 50(4):538-41. PubMed ID: 17900452
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost analysis of an intravenous to subcutaneous epoetin α conversion.
    Wazny LD; Raymond CB; Sood AR; Eng A; Verrelli M
    Am J Nephrol; 2013; 38(6):496-500. PubMed ID: 24334854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA; Walker R
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
    Chacón-Araya M; Rey-Rodríguez D; Rodríguez De León F; Ramos-Esquivel A; Sunning T
    J Med Econ; 2019 Aug; 22(8):736-741. PubMed ID: 30915883
    [No Abstract]   [Full Text] [Related]  

  • 10. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Pockros PJ; Shiffman ML; Schiff ER; Sulkowski MS; Younossi Z; Dieterich DT; Wright TL; Mody SH; Tang KL; Goon BL; Bowers PJ; Leitz G; Afdhal NH;
    Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin in haemodialysis patients: impact of change from subcutaneous to intravenous routes of administration.
    Decaudin B; Lemaitre V; Gautier S; Urbina MA
    J Clin Pharm Ther; 2004 Aug; 29(4):325-9. PubMed ID: 15271099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing anaemia management with subcutaneous administration of epoetin.
    Besarab A
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
    Linde T; Furuland H; Wikström B
    Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
    Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
    J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of illegal trade on the quality of epoetin alfa in Thailand.
    Fotiou F; Aravind S; Wang PP; Nerapusee O
    Clin Ther; 2009 Feb; 31(2):336-46. PubMed ID: 19302906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks.
    Naughton CA; Duppong LM; Forbes KD; Sehgal I
    Am J Health Syst Pharm; 2003 Mar; 60(5):464-8. PubMed ID: 12635452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.